HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation by K.B. Myant et al.
Research Article
HUWE1 is a critical colonic tumour suppressor gene
that prevents MYC signalling, DNA damage
accumulation and tumour initiation
Kevin B Myant1,2,* , Patrizia Cammareri1, Michael C Hodder1, Jimi Wills2, Alex Von Kriegsheim2,
Balázs Gy}orffy3,4, Mamun Rashid5, Simona Polo6, Elena Maspero6, Lynsey Vaughan7, Basanta Gurung8,
Evan Barry8, Angeliki Malliri7, Fernando Camargo8, David J Adams5, Antonio Iavarone9,
Anna Lasorella10 & Owen J Sansom1,**
Abstract
Cancer genome sequencing projects have identified hundreds of
genetic alterations, often at low frequencies, raising questions as to
their functional relevance. One exemplar gene is HUWE1, which has
been found to be mutated in numerous studies. However, due to the
large size of this gene and a lack of functional analysis of identified
mutations, their significance to carcinogenesis is unclear. To deter-
mine the importance of HUWE1, we chose to examine its function in
colorectal cancer, where it is mutated in up to 15 per cent of tumours.
Modelling of identified mutations showed that they inactivate the E3
ubiquitin ligase activity of HUWE1. Genetic deletion of Huwe1 rapidly
accelerated tumourigenic in mice carrying loss of the intestinal
tumour suppressor gene Apc, with a dramatic increase in tumour initi-
ation. Mechanistically, this phenotype was driven by increased MYC
and rapid DNA damage accumulation leading to loss of the second
copy of Apc. The increased levels of DNA damage sensitised Huwe1-
deficient tumours to DNA-damaging agents and to deletion of the
anti-apoptotic protein MCL1. Taken together, these data identify
HUWE1 as a bona fide tumour suppressor gene in the intestinal epithe-
lium and suggest a potential vulnerability of HUWE1-mutated tumours
to DNA-damaging agents and inhibitors of anti-apoptotic proteins.
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Introduction
The sequencing of human cancer genomes has led to a paradigm
shift in our understanding of oncogenesis (Vogelstein et al, 2013).
These studies have identified hundreds of genetic alterations that
broadly segregate into two distinct groups, a small number of
“mountains” (genes commonly mutated) and a large number of
“hills” (gene mutated at low frequency). Whereas the causative
role of frequently mutated genes is often clear, the role of those
less commonly mutated can be difficult to separate from muta-
tional “noise”. Determining the relevance of low-frequency muta-
tions is important for providing a comprehensive understanding
of the processes driving tumourigenic. To date, most attempts at
determining the relevance of such mutations have relied on
computational approaches, mining large multi-cancer databases
(Alexandrov et al, 2013; Lawrence et al, 2014). Whilst important,
these approaches provide only correlative evidence and, as such,
direct, functional testing remains the key determinant of the onco-
genic potential of somatic mutations (Kadoch & Crabtree, 2013;
Lewis et al, 2013).
HUWE1 is an X-linked E3 ubiquitin ligase mutated at moderate
frequencies (up to 15%) in a wide range of cancers including
colorectal, uterine, gastric, cervical, melanoma and lung (Hodis
et al, 2012; TCGA, 2012, 2014). HUWE1 catalyses the attachment of
both lysine 48 (K48)- and lysine 63 (K63)-linked polyubiquitin
chains, impacting on the function of a number of proteins involved
in tumourigenic. The outcome of HUWE1-mediated K48 and K63
ubiquitination is quite different. For example, HUWE1 regulates the
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stability of MCL1 and TP53 via addition of K48-linked polyubiquitin
chains (Chen et al, 2005; Zhong et al, 2005). Additionally, two
recent studies have described a role for HUWE1 in DNA damage
response and the regulation of genomic stability, again via K48-
linked modulation of H2AX and PCNA stability (Atsumi et al, 2015;
Choe et al, 2016). In contrast, HUWE1 regulates the function of
DVL, a component of the WNT signalling pathway, via K63-linked
ubiquitination (de Groot et al, 2014). This attachment prevents
multimerisation of DVL, which is necessary for its role in binding
AXIN2 during WNT signalling activation. Thus, HUWE1-mediated
ubiquitination of DVL suppresses WNT activation. Perhaps most
controversial is the role of HUWE1 in regulating MYC function. It
has been reported that HUWE1 mediates K63 ubiquitination
promoting the transcriptional activity of MYC, providing a pro-
oncogenic function (Adhikary et al, 2005). However, HUWE1 has
also been suggested to regulate the stability of both MYC during
skin carcinogenesis and MYCN during brain development via
K48 ubiquitination (Zhao et al, 2008; Inoue et al, 2013).
Together, these studies produce contrasting predictions, one
where HUWE1 may drive cancer via activation of MYC function
and one where loss of HUWE1 would promote cancer by increas-
ing levels of MYC, DNA damage and genomic instability. Thus
far, evidence from cell line and xenograft studies exists to
support both models, but genetic evidence from a skin cancer
model showed Huwe1 deletion accelerated tumourigenic suggest-
ing a tumour suppressor role (Inoue et al, 2013). Mechanistically,
the authors report Huwe1 deletion leading to accumulation of the
MYC/MIZ1 complex which, via direct promoter binding,
suppresses expression of the anti-proliferative P21 and P15 genes
(Inoue et al, 2013). Thus, in this model Huwe1 suppresses
tumourigenic primarily via anti-proliferative effects. However, the
relevance of this model to human cancer is unclear as HUWE1
mutations have not yet been observed in the currently limited,
cutaneous squamous cell carcinoma sequencing studies (Lee
et al, 2014).
Colorectal cancer (CRC), the second most common cause of
cancer-related mortality, is a disease characterised by WNT signal-
ling activation. Around 80% of tumours carry inactivating muta-
tions in the APC gene, a key inhibitor of the WNT pathway. These
mutations lead to a deregulation of WNT signalling that drives
transformation of the intestinal epithelium. Particularly pertinent
are our previous studies that show that Myc (a WNT target gene)
and its downstream signalling targets are essential for the phenotype
of deletion of Apc in vivo (Sansom et al, 2007; Myant et al, 2013;
Faller et al, 2015). Indeed, haploinsufficiency for Myc can reduce
the phenotypes of Apc loss and slow tumourigenic (Athineos &
Sansom, 2010). This, in concert with the most frequent mutation of
HUWE1 in CRC, makes it an ideal model to characterise HUWE1
function. Here, we robustly characterise the role of HUWE1 in CRC
initiation. We find inactivating HUWE1 mutations in human CRC
and that deletion of Huwe1 in CRC mouse models leads to rapid
tumourigenic and hugely increased tumour initiation. MYC protein
levels are increased and drive increased tumour proliferation but
are not the primary cause of the increased tumour initiation. Rather,
accumulation of DNA damage, characterised by accumulation of
c-H2AX leading to accelerated Apc loss, promotes tumour initiation.
These tumours display increased sensitivity to DNA-damaging
agents and are dependent on high levels of MCL1 for their survival
suggesting a potential therapeutic vulnerability of HUWE1-mutated
tumours. Together, these data define HUWE1 as a critical intestinal
tumour suppressor gene that restrains cellular proliferation and
DNA damage accumulation.
Results
HUWE1 is a colonic tumour suppressor
HUWE1 is a pleiotropic E3 ubiquitin ligase that modulates the func-
tion of several proteins involved in oncogenesis and DNA damage
response including MYC, MYCN, MCL1 and H2AX (Adhikary et al,
2005; Zhong et al, 2005; Zhao et al, 2008; de Groot et al, 2014).
Previous sequencing studies have identified somatic mutations
throughout the HUWE1 gene in up to 15% of colorectal tumours
(Wood et al, 2007; Seshagiri et al, 2012; TCGA, 2012; Fig EV1A).
HUWE1 is a large gene (~15,000-bp cDNA), and thus, its frequent
mutation could simply be a product of mutational “noise”. Huwe1
was also identified as a high-ranking positive hit in a CRC trans-
poson mutagenesis screen (rank 66/752) indicating its mutation
may be important to colorectal tumourigenic, but to date direct
functional determination of this is lacking (March et al, 2011).
Among many cancer types, CRC harbours the highest frequency of
HUWE1 mutations (Fig EV1B). However, the consequence of these
mutations on the function of HUWE1 remains undetermined. To
decipher the functional significance of HUWE1 mutations, we inter-
rogated the activity of two CRC-specific mutations targeting the
HECT domain of HUWE1 (R4082H and K4204del; Wood et al, 2007;
Jones et al, 2008). Following expression and purification of the
wild-type and mutant HECT domains of HUWE1, we found that
both mutations led to marked inhibition of the ability of the
HUWE1-HECT domain to bind to the E2-ubiquitin-conjugating
enzyme UbcH7, thus indicating that the two mutants perturb the
assembly of the HUWE1 ubiquitin ligase complex (Fig EV1C). As
HUWE1 is an X-linked gene that is transcriptionally silenced on the
inactive X, mutation of a single allele would be sufficient to disrupt
its activity (Carrel & Willard, 2005). Thus, we have identified poten-
tially functionally inactivating mutations of HUWE1 in primary
colorectal tumours. We next addressed the consequence of HUWE1
loss of function upon intestinal tumour development. We generated
a cohort of mice carrying an inducible floxed allele of Apc580S (from
here on referred to as Apcfl) under the control of the villin-Cre-ERT2
transgene (vil-Cre-ERT2 Apcfl/+— Vil Apc). Following recombina-
tion, these mice lose the wild-type Apc allele spontaneously and
succumb to small intestinal and colonic tumourigenic. We crossed
these mice to those carrying a conditional deletion allele of Huwe1
(Huwe1fl) to generate experimental cohorts of both female vil-Cre-
ERT2 Apcfl/+ Huwe1fl/+ (Vil Apc Huwe1het) and female or male vil-
Cre-ERT2 Apcfl/+ Huwe1fl/fl/Huwe1fl/y mice (Vil Apc Huwe1hom),
respectively. Following Cre induction with tamoxifen, we aged these
mice until signs of intestinal tumourigenic became apparent (pale
feet, hunching and weight loss). Whereas control mice survived to a
median of ~250 days, both Huwe1 mutant cohorts succumbed to
rapid tumourigenic (Huwe1het ~140 days, Huwe1hom ~90 days;
Fig 1A). Strikingly, macroscopic and microscopic analysis of the
guts from sacrificed mice indicated a dramatic increase in tumour
number upon Huwe1 deletion (Figs 1B–D and EV1D). Unlike Vil
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Apc mice that developed around five tumours, those from both the
Vil Apc Huwe1het and Vil Apc Huwe1hom cohorts developed around
200 (Fig 1D). This significant increase in tumour number was also
observed in the colons of homozygous deleted animals
(Fig EV1D). Immunohistochemical analysis of these tumours
demonstrated nuclear accumulation of b-catenin in Huwe1hom
tumours at a similar level as control tumours indicating that
tumour initiation was due to activation of WNT signalling
(Fig EV2A–C). These data define Huwe1 as an intestinal and
colonic tumour suppressor in the context of Apc heterozygosity
whose loss of function leads to increased tumour initiation.
Huwe1 deletion leads to perturbed intestinal homoeostasis
Given this profound impact on tumour formation, we next analysed
whether Huwe1 deletion impacted on intestinal homoeostasis. Histo-
logical examination of Huwe1-deficient intestines 14 days post-
induction showed modest changes in crypt/villus architecture with
D
A
p < 0.0001
p = 0.0017 p = 0.0537
Vil Apc Vil Apc Huwe1hom
C
B
Vil Apc
Vil Apc Huwe1het
Vil Apc Huwe1hom
Vil Apc Vil Apc Huwe1hom
Figure 1. Huwe1 is an intestinal tumour suppressor gene.
A Kaplan–Meier survival plot of cohorts of induced Vil Apc, Vil Apc Huwe1het and Vil Apc Huwe1hom mice. Deletion of Huwe1 led to a significant reduction in survival of
these animals (Vil Apc versus Vil Apc Huwe1het/Vil Apc Huwe1hom, log rank, P < 0.001, n ≥ 10).
B Wholemount isolation of small intestines from Vil Apc and Vil Apc Huwe1hom mice culled at clinical endpoint. Note the huge numbers of tiny macroscopic adenomas
visible in the Vil Apc Huwe1hom intestine (red arrows).
C H&E staining of intestinal cross sections from Vil Apc and Vil Apc Huwe1hom mice demonstrating the increased adenoma burden following Huwe1 deletion. Black
arrows indicate individual adenomas. Scale bars = 200 lm.
D Quantification of total tumour numbers per gut in sacrificed Vil Apc, Vil Apc Huwe1het and Vil Apc Huwe1hom mice. Deletion of Huwe1 led to a significant increase in
the number of tumours per gut (Mann–Whitney, n ≥ 5). Mean and standard deviation are plotted.
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slightly shortened villi, but both cellular proliferation and apoptosis
were unchanged (Fig 2A and B, and Appendix Figs S3A and S6A).
We next analysed whether Huwe1 loss altered intestinal cellular dif-
ferentiation by examining markers of different intestinal cell popula-
tions. Interestingly, whilst we observed no gross changes in the
number of goblet cells by periodic acid–Schiff (PAS) staining
(Fig 2C), we observed lysozyme expression away from the intestinal
crypt base (Fig 2D and Appendix Fig S3B and C). This could indi-
cate either mislocalisation of Paneth cells or perturbed secretory
intestinal differentiation. To investigate this more closely, we
carried out double staining with PAS and alcian blue which marks
Paneth cell secretory vesicles and goblet cells. This demonstrated
that Paneth cell secretory vesicles are maintained at the crypt base
in Huwe1-deficient intestines, suggesting that the lysozyme-positive
cells may be cells from a different lineage expressing lysozyme
(Fig 2E). Additionally, immunohistochemical analysis indicated that
expression of the Paneth cell marker MMP7 was retained at the
crypt base following HUWE1 deletion (Fig 2F). Furthermore, under
closer scrutiny the lysozyme-positive cells further up the crypt–
villus axis appear to have the morphology of goblet cells (Fig EV3D)
suggesting alterations in secretory cell marker expression. Both
Paneth cell differentiation (Andreu et al, 2008) and EPHB/EPHRINB
gradient-mediated localisation (Batlle et al, 2002; Sansom et al,
2004) are controlled by WNT signalling. A recent study has
suggested a role for HUWE1 as a negative regulator of WNT signal-
ling (Dominguez-Brauer et al, 2016), so we analysed the expression
of a number of WNT target genes 14 days after Huwe1 deletion.
Interestingly, we observed a modest increase in expression of a
number of WNT target genes, including Ephb3, which is a critical
mediator of Paneth cell localisation (Fig EV3E; Batlle et al, 2002).
However, not all of the analysed WNT target genes showed
increased expression, and once Apc was deleted, we no longer saw
a HUWE1-dependent modification of WNT target genes, with the
robust induction of targets caused by Apc loss masking any impact
of HUWE1 (Fig EV3F). Thus, it is possible these changes reflect
secondary consequences of Huwe1 deletion effects on crypt
homoeostasis. We next performed microarray analysis comparing
wild-type to HUWE1-deficient intestines to assess whether WNT
signalling was globally deregulated following Huwe1 deletion. This
was conducted at 4 days post-Huwe1 deletion to reduce potential
secondary consequences of Huwe1 loss. We identified 586 and 415
genes whose expression was significantly up- or down-regulated,
respectively (Appendix Table S1). The upregulated data set included
a number of WNT-responsive intestinal stem cell marker genes
including Ascl2, Lect2, Slc14a1 and Nrn1. Gene set enrichment anal-
ysis identified a highly significant overlap of transcriptional markers
of intestinal stem cells (chi-squared test with Yates’s correction,
P < 0.0001; Munoz et al, 2012) between the gene lists, demonstrat-
ing elevated expression of some members of the intestinal stem cell
signature following Huwe1 deletion. However, well-known WNT
target genes such as Axin2 and Myc were not upregulated and gross
changes in nuclear b-catenin localisation were not observed
(Fig EV3G), suggesting that HUWE1 loss only modifies the expres-
sion of subset of WNT target genes associated with stem cell mark-
ers. Together, these data identify a role for HUWE1 loss in moderate
amplification of intestinal WNT signalling, expression of some stem
cell-related genes and perturbed homoeostasis. However, given the
redundancy of both stem cell markers (e.g. Lgr5) and Paneth cells
for intestinal homoeostasis and tumourigenic (de Lau et al, 2011;
Durand et al, 2012), we felt these could not explain the marked
increase in tumourigenic we observed.
MYC drives increased tumour proliferation following
Huwe1 deletion
We next wanted to address the mechanism via which HUWE1
suppresses tumourigenic. Of particular relevance is the proposed
role of HUWE1 in regulating MYC, a key downstream mediator of
HUWE1 function (Inoue et al, 2013). As MYC is a critical modulator
of intestinal tumourigenic, we hypothesised that the modulation of
MYC stability may be a key tumour-suppressive function of HUWE1
within the gut (Sansom et al, 2007; Athineos & Sansom, 2010). We
addressed this by determining MYC expression in epithelial extrac-
tions of control and Huwe1-deficient intestines. We found a signifi-
cant increase in MYC protein, but not transcript, following HUWE1
loss (Fig 3A and B). This increase in MYC protein was also observed
in Huwe1-deficient Vil Apc Huwe1 tumours compared to controls
and was independent of transcriptional effects (Fig 3C–E). These
data indicate that HUWE1 controls MYC protein abundance in both
normal intestine and intestinal tumours.
We next sought to determine whether MYC function is important
for driving the dramatic phenotypes we observe upon Huwe1 dele-
tion. This was determined using both loss- and gain-of-function alle-
les of Myc. As Myc deletion rescues the phenotypes of Apc loss in
the small intestine, complete ablation of Myc in the context of addi-
tional Huwe1 deletion would likely yield the same phenotype.
Moreover, as Myc haploinsufficiency slows Apc-dependent
tumourigenic, one would expect it to also slow the Vil Apc Huwe1
phenotype. Therefore, we wanted to find a system where tumouri-
genic is insensitive to a 50% reduction in Myc to permit assessment
of the role of Huwe1 in this context. In CRC, mutation and epige-
netic inactivation of the PI3K–PTEN pathway occur in up to 40% of
cases, and we have shown that Pten deletion rapidly accelerates
tumourigenic and drives tumour progression (Marsh et al, 2008).
Pten heterozygosity, however, only causes a relatively mild increase
in tumourigenic. We therefore thought this model would be an ideal
candidate to examine (i) whether Huwe1 loss can accelerate
tumourigenic in multiple spontaneous models and (ii) whether Myc
is functionally important for this. We first confirmed that deletion of
Huwe1 accelerates tumourigenic in a spontaneous model with addi-
tional Pten deletion by ageing cohorts of vil-Cre-ERT2 Apcfl/+ Ptenfl/+
(Vil Apc Pten) and vil-Cre-ERT2 Apcfl/+ Ptenfl/+ Huwe1fl/fl (Vil Apc
Pten Huwe1) mice. Consistent with our previous model, Huwe1 dele-
tion led to a dramatic shortening of lifespan and a marked increase
in tumour number and increased tumour cell proliferation (Figs 4A
and B, and EV4A and B). We next determined whether this model is
sensitive to reduced Myc expression by comparing survival of the Vil
Apc Pten mice to those with additional deletion of a single Myc allele
(vil-Cre-ERT2 Apcfl/+ Ptenfl/+ Mycfl/+—Vil Apc Pten Myc). Interest-
ingly, we found neither survival of mice with Pten deletion nor
tumour cell proliferation was sensitive to loss of a single Myc allele
(Figs 4A and B, and EV4A and B). Therefore, this model is ideal for
defining the functional relevance of elevated MYC levels in Huwe1-
deficient tumours. We generated vil-Cre-ERT2 Apcfl/+ Ptenfl/+
Huwe1fl/fl Mycfl/+ (Vil Apc Pten Huwe1 Myc) mice and compared
their survival to the Vil Apc Pten Huwe1 cohort. Strikingly, in the
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context of Huwe1 deletion, reduced expression ofMyc led to a signifi-
cant increase in survival, thus indicating that the tumour suppressor
function of HUWE1 is, at least in part, mediated through the control
of MYC stability (Fig 4A). However, despite the enhanced survival,
Vil Apc Pten Huwe1 Myc mice showed no reduction in tumour
number (Fig 4B). They did, however, show decreased tumour
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Figure 2. Huwe1 deletion leads to perturbed intestinal homoeostasis.
A H&E staining of control and Huwe1-deleted intestinal epithelium. Shortened villi in Huwe1-deficient tissue are indicated.
B BrdU IHC of control and Huwe1-deleted intestinal epithelium.
C PAS staining identifying goblet cells. No gross changes were observed.
D Lysozyme staining (Paneth cell marker) of control and Huwe1-deleted small intestine. Note the occurrence of lysozyme-positive cells away from the crypt base
(black arrows).
E Dual periodic acid–Schiff/alcian blue staining to identify Paneth cell secretory vesicles (light blue/pink, marked with black arrows) and goblet cells (dark blue/purple,
marked with red arrows). Note Paneth cell secretory vesicles are restricted to crypt base in both control and Huwe1-deficient small intestines (inset, black arrows).
F MMP7 staining of control and Huwe1-deleted small intestine. Note MMP7 staining is restricted to crypt base in Huwe1-deficient intestines.
Data information: Scale bars = 100 lm.
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proliferation rates compared to tumours from Vil Apc Pten Huwe1
mice (Fig EV4A and B). These data suggest that MYC accumulation
in this model promotes tumour growth, but the residual MYC levels
in the Mycfl/+ background are sufficient for efficient tumour
initiation. We further characterised the role of increased MYC protein
during tumourigenic by overexpressing two copies of a proteolyti-
cally stable MYC mutant (Rosa-lsl-MycT58A) in this model (Apc Pten
MycT58A). Consistent with our loss-of-function experiments,
A
WT Huwe1
α-HUWE1 n/s
B
α-MYC (low exp)
α-MYC (high exp)
α-β-actin
C 1ewuHcpAliVcpAliV hom
α-
M
Y
C
α
D n/s
E
Vil Apc Vil Apc Huwe1hom
α-MYC
α-βactin
Figure 3. Increased MYC protein expression following Huwe1 deletion.
A HUWE1 and MYC Western blot analysis of epithelial cell extractions from control and Huwe1-deficient intestines. Levels of MYC protein are significantly increased in
normal intestines lacking HUWE1 (Mann–Whitney, P = 0.04, n = 3).
B qRT–PCR analysis of Myc expression in control and Huwe1-deficient intestines. Mann-Whitney, n = 4 vs 6. Data plotted are mean and SD.
C MYC IHC in tumours from Vil Apc and Vil Apc Huwe1hom mice. Scale bars = 50 lm.
D MYC Western blot in protein extracts from Vil Apc and Vil Apc Huwe1hom tumours. Levels of MYC protein are significantly increased in tumours lacking HUWE1
(Mann–Whitney, P = 0.04, n = 3).
E qRT–PCR analysis of Myc expression in tumours from Vil Apc and Vil Apc Huwe1hom mice. Mann-Whitney, n = 3 vs 3. Data plotted are mean and SD.
Source data are available online for this figure.
EMBO Molecular Medicine Vol 9 | No 2 | 2017 ª 2016 Cancer Research UK Beatson Institute
EMBO Molecular Medicine HUWE1 is a critical colonic tumour suppressor Kevin B Myant et al
186
Published online: December 21, 2016 
overexpression of MYCT58A significantly decreased survival but had
no effect on overall tumour number (Fig 4C and D). In human CRC,
we found that HUWE1 mutations were mutually exclusive with
amplifications, gains and transcriptional upregulation of MYC
(P = 0.042; Fig 4E). This suggests that HUWE1 mutation in human
CRC might facilitate increased levels of MYC and bypass the require-
ment for genomic amplification. However, it is also clear from our
work, and others, that MYC levels are sufficiently high for transfor-
mation in the presence of HUWE1 and reduction or overexpression
of MYC does not have a profound impact on tumour initiation.
BA
p = 0.002 
p = 0.8768 
p = 0.0001 
DC
p < 0.001
p = 0.17
E
Apc Pten
Apc Pten MycT58A
Figure 4. MYC upregulation following Huwe1 deletion drives accelerated tumourigenic.
A Kaplan–Meier survival plot of cohorts of induced Vil Apc Pten, Vil Apc Pten Huwe1, Vil Apc Pten Myc and Vil Apc Pten Huwe1 Myc mice. Heterozygous deletion of
Myc led to a specific and significant increase in survival of Huwe1-deleted animals (Vil Apc Pten Huwe1 versus Vil Apc Pten Huwe1 Myc, log rank, P < 0.001, n ≥ 16).
B Quantification of total tumour numbers per gut in sacrificed Vil Apc Pten, Vil Apc Pten Huwe1, Vil Apc Pten Myc and Vil Apc Pten Huwe1 Myc mice. Heterozygous
deletion of Myc did not reduce the number of tumours in Huwe1-deleted mice (Vil Apc Pten Huwe1 versus Vil Apc Pten Huwe1 Myc, Mann–Whitney, n ≥ 10). Data
plotted are mean and SD.
C Kaplan–Meier survival plot of cohorts of induced AhCre-ERT Apc Pten and AhCre-ERT Apc Pten MycT58A mice. Overexpression of proteolytically stabilised MYC led to a
significant reduction in survival (log rank, P < 0.001, n = 14 versus 21).
D Quantification of total tumour numbers per gut in sacrificed Apc Pten and Apc Pten MycT58A mice. Overexpression of proteolytically stabilised MYC did not increase
the number of tumours in Apc Pten mice (Mann–Whitney, n = 9 versus 19). Data plotted are mean and SD.
E cBioportal OncoPrint showing mutual exclusivity of HUWE1mutations and increased MYC copy number and/or RNA expression in CRC samples (log odds ratio: 1.144
[some tendency towards mutual exclusivity], P = 0.042).
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Taken together, the above findings indicate that, besides MYC, other
substrates of HUWE1 contribute to intestinal tumourigenesis in
Huwe1-null mice.
Huwe1 deletion leads to increased levels of DNA damage
The massively increased tumour number we observed was reminis-
cent of mice displaying a mutator phenotype, such as those deficient
for Mlh1 or Msh2 (Reitmair et al, 1996; Edelmann et al, 1999). We
reasoned that increased tumour initiation in mice heterozygous for
Apc loss would most likely occur via increased DNA damage and/or
mutation rate. Two recent reports have described a role for HUWE1
in regulation of DNA damage response and genomic stability via
degradation of H2AX and PCNA, respectively (Atsumi et al, 2015;
Choe et al, 2016). To attempt to define the mechanism by which
Huwe1 deletion drives increased tumourigenic, we carried out mass
spectrometry analysis to compare the proteome of normal and
Huwe1-deficient intestinal tissue. Interestingly, this analysis identi-
fied a significant increase in H2AX levels following Huwe1 deletion
that we confirmed by Western blot (Appendix Table S2 and Fig 5A).
Thus, loss of Huwe1 function could lead to accumulation of DNA
damage via accumulation of H2AX leading to inefficient resolution
of c-H2AX foci (Atsumi et al, 2015). To test this hypothesis, we
analysed DNA damage levels following Huwe1 deletion. Interest-
ingly, we observed increased levels of c-H2AX in normal intestine
and tumour tissue deficient for Huwe1 (Fig 5B–D and Appendix Fig
S5A). We next used PCR analysis of the Apc locus to determine the
mechanism by which Huwe1-deficient cells lose Apc. The majority
of both control and Huwe1-deficient tumours demonstrated loss of
heterozygosity at the Apc locus indicating that Apc loss is driving
tumour initiation (Fig EV5B). A common property of cells with
increased levels of DNA damage is an increased sensitivity to DNA-
damaging agents (Farmer et al, 2005; Hay et al, 2005). To investi-
gate this further, we treated both control and tumour-bearing mice
with the DNA-cross-linking agent cisplatin. Consistent with the
observed increase in DNA damage, Huwe1-deficient tumours
displayed increased sensitivity to this treatment with significantly
higher levels of apoptosis (Fig 6A and B). Together, these data
demonstrate that loss of Huwe1 leads to accumulation of DNA
damage, loss of Apc and subsequent tumour initiation. We next
analysed tumour data from TCGA to determine whether HUWE1
loss of function can confer a similar DNA damage phenotype in
human disease. We found that tumours carrying HUWE1 mutations
displayed a far higher somatic mutational burden than those with
wild-type HUWE1 (Fig 6C). Importantly, this increase was indepen-
dent of MLH1 silencing, a key determinant of mutational burden
indicating this is not merely a consequence of a general increased
mutation rate (Fig 6D). Thus, increased DNA damage appears to be
a property of HUWE1 mutation in human CRC and may confer a
therapeutic vulnerability on these tumours during tumourigenic.
One prediction of increased sensitivity to DNA-damaging agents
upon HUWE1 loss would be that tumours that had low levels of
HUWE1 might respond better to therapy. There are currently no
data publically available on the treatment response of HUWE1-
mutated patients, so we analysed this with respect to HUWE1
expression levels. We found that patients whose tumours express
low levels of HUWE1 have significantly increased overall survival
following chemotherapy treatment than those expressing higher
levels (Fig 6E). Interestingly, there were no significant survival dif-
ferences between patients who received no adjuvant chemotherapy
treatment based on HUWE1 expression levels (Fig 6F). These data
are consistent with an increased DNA damage burden in human
tumours depleted of HUWE1 and may suggest that patients with
HUWE1 mutations may respond better to chemotherapeutic
treatment.
Given this increased DNA damage even in intestines that were
wild-type for Apc, this could suggest that Huwe1 loss increases
tumour initiation by promoting loss of the wild-type Apc allele. To
test whether Huwe1 loss accelerates tumourigenic independently of
the requirement for loss of wild-type Apc, we utilised a model initi-
ated by homozygous deletion of Apc. Using the Lgr5-cre-ERT2 knock-
in mouse, both copies of Apc alone or in combination with Huwe1
can be deleted specifically in stem cells (Fig 7A). This model
permits rapid tumourigenic originating from LGR5-positive intesti-
nal stem cells. We generated cohorts of Lgr5-cre-ERT2 Apcfl/fl (Lgr5
Apc) and Lgr5-cre-ERT2 Apcfl/fl Huwe1fl/fl (Lgr5 Apc Huwe1) mice
and aged them until they showed signs of tumourigenic (Fig 7B). In
this model, there was a less dramatic (median survival 50 versus
43 days) though significant decrease in survival of Lgr5 Apc Huwe1
mice compared to Lgr5 Apc (P < 0.001; Fig 7B). This indicates that
HUWE1 suppresses intestinal tumourigenic at multiple levels, in
part by stopping tumour initiation but (and consistent with the data
on MYC above) also at the level of tumour growth. To determine
whether the lysozyme expression and stem cell phenotypes were
maintained in tumour tissue, we analysed lysozyme and OLFM4
expression in these tumours. We observed both increased lyso-
zyme-positive cell abundance and zone of OLFM4 expression in
Huwe1-deficient tumours (Fig 7C and D). Thus, even in the absence
of Apc loss of Huwe1 perturbed differentiation.
One very surprising observation was that despite the dramati-
cally increased DNA damage burden, we did not observe an
increase in apoptosis in Huwe1-deficient crypts (Fig EV6A). Intesti-
nal epithelial cells are extremely sensitive to DNA damage-induced
apoptosis and equivalent levels of c-H2AX would normally lead to
high levels of apoptosis, suggesting that Huwe1-deficient cells are
protected from cell death (Phesse et al, 2014). HUWE1 has previ-
ously been implicated in modulating the stability of the anti-apop-
totic protein MCL1 and so we hypothesised that increased levels of
MCL1 may protect Huwe1-deficient cells from death (Zhong et al,
2005). We observed increased levels of MCL1 in tumour tissue defi-
cient for Huwe1 (Fig 8A). To determine whether increased MCL1
levels protect Huwe1-deficient cells from apoptosis, we generated
VilCreERT2 Huwe1fl/fl Mcl1fl/+ (Huwe1 Mcl1) mice and induced
simultaneous deletion of Huwe1 and one copy of Mcl1. The intesti-
nes of these mice displayed significantly higher levels of apoptosis
than singly deleted Huwe1 mice demonstrating a role for MCL1 in
protecting Huwe1-deficient cells from apoptosis in homoeostatic
conditions (Fig EV6A). Importantly, deletion of one copy of Mcl1
alone did not induce an apoptotic response suggesting this observa-
tion was specific to Huwe1 loss-mediated DNA damage (Fig EV6A).
We next addressed whether this impacted on tumour development
by generating a cohort of tumour-inducible mice carrying the same
Mcl1fl/+ allele. Similar to our observations in normal tissue, we
found that heterozygous deletion of Mcl1 reduced Huwe1 loss-
driven tumourigenic (Fig 8B). Mice heterozygous for Mcl1 displayed
a greater propensity to form indolent lesions than the mice wild-type
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for Mcl1. The ratio of canonical adenomas to indolent lesions, iden-
tified as a spherical lesion usually contained entirely within a single
villus, was significantly different between the genotypes (Fig 8C and
Appendix Fig S6B and C). Together, these data indicate that Huwe1
loss of function leads to increased levels of MCL1 protein and this
protects cells from DNA damage-induced apoptosis facilitating onco-
genic transformation.
Discussion
The identification of hundreds of somatic mutations in cancer
genomes has raised critical questions as to their functional rele-
vance. Despite efforts to analyse such mutations computationally,
our work demonstrates the importance of direct functional testing,
in particular of large genes mutated at moderate levels. Our work
shows, by robust genetic characterisation, that Huwe1 is a tumour
suppressor in the small intestine and colon. Together with our iden-
tification of HUWE1 mutations present in human CRC that perturb
its ubiquitin ligase activity, this strongly suggests it is a bona fide
colonic tumour suppressor gene.
This is particularly important as previous work on HUWE1’s
tumourigenic role had proven controversial. HUWE1 is an E3 ubiq-
uitin ligase that controls the stability of MCL1, MYC and MYCN
functions which would suggest a tumour-suppressive role. Indeed,
work using chemically induced skin cancer mouse models has indi-
cated this is the case (Inoue et al, 2013). However, via K63-
mediated ubiquitination, HUWE1 is required for the transactivation
function of MYC and tumour cell proliferation. It is also overex-
pressed in a number of different cancers including colorectal,
supporting a pro-oncogenic function (Adhikary et al, 2005). Using
intestinal and colonic specific gene deletion, we show that loss of
Huwe1 leads to significantly accelerated tumourigenic characterised
by a massive increase in tumour incidence. We observe coincident
increased MYC protein levels and, using conditional co-deletion of
Myc, we demonstrate this increase in MYC is an important mediator
of this phenotype. The mutual exclusivity of HUWE1 mutation and
MYC genomic amplification we observe in human CRC strongly
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Figure 5. Huwe1 deletion leads to an increase in DNA damage.
A H2AX Western blot in protein extracts from control and Huwe1-deficient intestinal epithelial cells. Band intensity relative to b-actin displayed under each lane
(Mann–Whitney, P = 0.04, n = 3 versus 3).
B c-H2AX IHC showing increased positivity in Huwe1-deleted intestinal cells (black arrows). Scale bars = 50 lm.
C c-H2AX Western blot in protein extracts from control and Huwe1-deficient intestinal epithelial cells (Mann–Whitney, P = 0.04, n = 3 versus 3).
D c-H2AX IHC of Vil Apc and Vil Apc Huwe1hom tumours; note increased positivity in Huwe1-deficient tumours. Scale bars = 50 lm.
Source data are available online for this figure.
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implicates them as critical mediators of colorectal tumourigenic.
Thus, our findings are consistent with a tumour-suppressive role of
HUWE1 in destabilising MYC post-translationally. The reason for
these discrepancies is not immediately clear although it is worth
noting the elevated levels of DNA damage we observed following
Huwe1 deletion in vivo. It is possible that some of the anti-prolifera-
tive effects the authors observe following HUWE1 knockdown are in
fact due to DNA damage-induced growth arrest that is more appar-
ent in cell culture conditions. Interestingly, Myc deletion does not
impact on the increased tumour initiation phenotype; rather, it
dampens the elevated tumour cell proliferation observed in Huwe1-
deficient tumours. This has the consequence of slowing the acceler-
ated tumour growth following Huwe1 loss but has no impact on the
ability of tumours to form. Thus, HUWE1 clearly impacts on
tumourigenic via multiple pathways.
Our observation that lysozyme expression becomes mislocalised
and the stem/progenitor cell zone was expanded is consistent with
a recent paper identifying HUWE1 in regulating the intestinal stem
cell niche via direct modulation of EPHB3 stability (Dominguez-
Brauer et al, 2016). However, we believe that the impact of Paneth
cell marker mislocalisation due to increased EPHB3 stabilisation is
insufficient to explain the tumourigenic phenotype observed in both
studies. Firstly, although expression of lysozyme was mislocalised,
Paneth cell secretory vesicles and MMP7 expression were not,
suggesting this phenotype may be the consequence of perturbed
lineage commitment rather than gross changes in Paneth cell locali-
sation. In addition, previous studies have shown induction of
Paneth cell mislocalisation via perturbation of EPHB/EPHRINB
gradient leads to modest changes in tumourigenic with the most
striking aspect being CRC progression. Of note, we did not observe
any invasive carcinomas in our Apcfl/+ Huwe1-deficient mice.
Rather, we observed an ~40-fold increase in tumour number
together suggesting changes in EPHB3 stabilisation are not the
primary cause of tumour initiation following Huwe1 deletion.
Notably, we also observed increased tumour formation initiated
directly from LGR5-positive stem cells in Huwe1-deficient intestines.
Using a stem cell-specific cre, we were able to show not only accel-
erated tumourigenic, but also maintenance of the lysozyme expres-
sion phenotype observed in normal tissue. As stem cells are
proposed to be the cell of origin of colorectal cancer (Barker et al,
2009), the increased propensity of those lacking Huwe1 to undergo
transformation may in part explain its tumour-suppressive role.
However, as yet there is no evidence that increased numbers of
intestinal stem cells would lead to transformation. Indeed, one
might predict that increased stem cell number might increase stem
cell competition, so the chance that a second mutation in APC is
fixed is reduced (Vermeulen et al, 2013). Moreover, we did not
observe tumour formation in intestines deficient for Huwe1 alone,
even a year post-induction suggesting that disruption of homoeosta-
sis (e.g. deregulation of stem cell markers and Paneth cells) was not
sufficient in driving carcinogenesis. The significance of previously
reported roles of HUWE1 and WNT signalling is still to be deter-
mined. We only saw activation of a subset of ISC signature WNT
targets and not general targets such as AXIN2, and there were no
changes in nuclear b-catenin. More importantly, all tumours lost the
second copy of Apc, and once this occurred, WNT target expression
was similar between wild-type and Huwe1-deficient intestines.
Together, this would suggest that neither the disruption of
homoeostasis nor WNT signalling can explain the rapid tumouri-
genic observed. Thus, we think it is most likely that tumours arise
due to different tumour-suppressive mechanisms exerted by
HUWE1.
Particularly pertinent to this was our observation of high levels
of DNA damage in Huwe1-deficient tissue and tumours. Our finding
that, in addition to increased levels of DNA damage, Huwe1-
deficient tumours display additional sensitivity to DNA-damaging
agents is in agreement with previous reports (Farmer et al, 2005;
Hay et al, 2005). A number of previous studies have identified
HUWE1 as an important mediator of DNA repair via modulation of
proteins such as MUTY, BRCA1, POLB and TP53 (Chen et al, 2005;
Parsons et al, 2009; Dorn et al, 2014; Wang et al, 2014). Interest-
ingly, alongside mediating DNA damage response, a recent paper
has identified a mechanism via which Huwe1 loss can drive DNA
damage accumulation. Choe and colleagues reported HUWE1
promotes replication of damaged DNA via interaction with PCNA
leading to efficient H2AX signalling (Choe et al, 2016). In the
absence of Huwe1, DNA damage accumulates and, similar to our
own findings, cells show increased sensitivity to DNA-damaging
agents. This is in agreement with another study identifying H2AX as
a direct target for HUWE1-mediated degradation (Atsumi et al,
2015) and our own findings that c-H2AX accumulates in intestinal
epithelial cells following Huwe1 deletion. Together, these data
suggest HUWE1 is a critical mediator of DNA damage response and
repair and loss of Huwe1 can drive DNA damage accumulation.
They also indicate an additional important facet of HUWE1-mutated
colorectal tumours—that they may be exquisitely sensitive to
DNA-damaging agents and may therefore respond better to them.
This is supported by our finding that patients whose tumours
◀ Figure 6. Huwe1-deficient tumours are sensitive to cisplatin treatment.A Caspase-3 IHC of tumours from Lgr5 Apc and Lgr5 Apc Huwe1 mice either untreated or treated with 7.5 mg/kg cisplatin 6 h post-treatment. Arrows identify caspase-
3-positive cells. Scale bars = 50 lm.
B Quantification of cisplatin treatment showing a significant increase in apoptosis in Huwe1-deficient tumour cells (Mann–Whitney, n = 3 versus 5). Data plotted are
mean and SD.
C Comparison of somatic mutation rate (mutations/Mb) between human tumours carrying HUWE1 mutations or not. Note the significant increase in mutational
burden in HUWE1-mutated tumours (Mann–Whitney, P = 0.0002, n ≥ 15). Data plotted are mean and SD.
D Comparison of somatic mutation rate (mutations/Mb) between human tumours carrying HUWE1 mutations or not grouped according to MLH1 status. Note that the
increased mutation rate is found primarily in tumours where MLH1 is not silenced indicating increased mutation rate (and HUWE1 mutation itself) is not due to
silencing of MLH1 (Mann–Whitney, P = 0.0007, n ≥ 11). Data plotted are mean and SD.
E Survival analysis of colorectal cancer patients treated with adjuvant chemotherapy divided by HUWE1 expression levels. Note the lowest HUWE1-expressing quartile
of patients respond significantly better to chemotherapy.
F Survival analysis of colorectal cancer patients not treated with adjuvant chemotherapy divided by HUWE1 expression levels. Note the lowest HUWE1-expressing
quartile of patients do not survive significantly longer than those expressing higher levels of HUWE1 if not treated with chemotherapy.
ª 2016 Cancer Research UK Beatson Institute EMBO Molecular Medicine Vol 9 | No 2 | 2017
Kevin B Myant et al HUWE1 is a critical colonic tumour suppressor EMBO Molecular Medicine
191
Published online: December 21, 2016 
express low levels of HUWE1 expression respond better to adjuvant
chemotherapy treatment than those with high levels of HUWE1.
Due to the relatively high prevalence of HUWE1 mutations in a
number of cancer types, this may indicate an important therapeutic
window for their treatment.
One unexpected finding was that cells in the small intestine toler-
ated accumulation of DNA damage following Huwe1 deletion with-
out undergoing apoptosis. This appears in conflict with previous
reports of sensitivity of intestinal cells to numerous DNA-damaging
agents (Phesse et al, 2014). Using genetic deletion of a single Mcl1
allele, we found that protection against cell death is conferred by
increased levels of the anti-apoptotic protein MCL1, a previously
described HUWE1 target (Zhong et al, 2005). Thus, tumour cell
survival in the context of increased DNA damage following Huwe1
deletion is partially dependent on increased levels of MCL1.
Currently, there is much excitement of the use of BCL2 family inhi-
bitors in hematopoietic malignancies such as CLL. Thus far, there
has not been such strong preclinical evidence that inhibition of
BCL2 family proteins will be effective for the treatment of late-stage
epithelial cancers. Recent studies have shown that intestinal stem
cells have high levels of BCL2 and that loss of BCL2 could slow
tumourigenic from Lgr5 stem cells (van der Heijden et al, 2016).
Our work here would suggest increased expression of MCL1 (a bona
fide HUWE1 target) in Huwe1-deficient cells might protect these
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Figure 7. Huwe1 loss promotes intestinal stem cell transformation.
A Schematic outlining Lgr5 Apc Huwe1 stem cell transformation/tumour model.
B Kaplan–Meier survival plot of cohorts of induced Lgr5 Apc and Lgr5 Apc Huwe1 mice. Deletion of Huwe1 led to a significant reduction in survival of these animals
(log rank, P < 0.001, n ≥ 15).
C Lysozyme IHC demonstrating increased lysozyme-positive cell numbers in tumours from Lgr5 Apc Huwe1 mice. Scale bars = 200 lm (low magnification), 100 lm
(high-magnification inset).
D OLFM4 IHC demonstrating expanded stem cell population in Lgr5 Apc Huwe1 tumours. Scale bars = 200 lm (low magnification), 100 lm (high-magnification inset).
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cells from death as haploinsufficiency for MCL1 markedly slowed
tumourigenic. Currently, MCL1 inhibitors are in development and
compounds are entering phase 1 trials. Thus, HUWE1 mutations
might allow enrichment for responders to MCL1 inhibition either
alone or in combination with other BCL2 family inhibitors or
chemotherapy.
Overall, we find that loss of Huwe1 function drives a potent
tumour initiation phenotype in the context of Apc heterozygosity.
This phenotype is mediated by a number of key pro-oncogenic
events including increased MYC stability, elevated DNA damage
and increased levels of MCL1 promoting stem cell transformation
and protection from cell death (Fig 8D). Together, our work defines
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Figure 8. Huwe1-deficient tumours tolerate high levels of DNA damage due to elevated MCL1.
A MCL1 Western blot in protein extracts from Vil Apc and Vil Apc Huwe1hom tumours. Levels of MCL1 protein are significantly increased in tumours lacking HUWE1
(Mann–Whitney, P = 0.04, n = 3).
B Kaplan–Meier survival plot of cohorts of induced Lgr5 Apc Huwe1 and Lgr5 Apc Huwe1 Mcl1het mice. Deletion of one copy of Mcl1 led to a significant increase in
survival of these animals (log rank, P = 0.0052, n = 9 versus 10).
C Ratio of adenoma/indolent lesions observed in Lgr5 Apc Huwe1 and Lgr5 Apc Huwe1 Mcl1het mice. Note the decreased ratio of adenoma/indolent lesions observed
upon Mcl1 deletion (Mann–Whitney, P = 0.0281, n = 8 versus 8).
D Schematic outlining the tumour-suppressive role of HUWE1. When HUWE1 is expressed, the amounts of MYC, c-H2AX and MCL1 are maintained at low levels.
Following HUWE1 mutation or loss MYC, c-H2AX and MCL1 levels are increased leading to increased levels of proliferation and DNA damage. This leads to loss of
Apc and tumour initiation. Increased MCL1 is critical to protect these cells from apoptosis induced by the high levels of DNA damage.
Source data are available online for this figure.
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a critical tumour suppressor pathway and provides the basis for
further dissection of its role in CRC.
Materials and Methods
Mouse experiments
All animal experiments were performed under UK Home Office
regulations (licence 70/8646) which underwent local ethical
review at Glasgow University prior to being carried out. The
backgrounds of mice used were mixed (50% C57BL/6J, 50%
S129). Mice of both sexes were used during these studies at
approximately equal ratios except for experiments analysing
Huwe1 heterozygous deletion where only females were used.
Animals were bred in positively pressurised IVC caging, and all
animal handling took place in change station or CAT11 hoods.
Cages were autoclaved prior to use, with irradiated diet and 0.1-
lm filter drinking water supplied by Hydropac. Animal holding
rooms are supplied with HEPA-filtered air and the rooms are posi-
tively pressurised in relation to the other parts of the facility. For
experimentation, animals were caged in conventional cages. These
cages were autoclaved prior to use, with irradiated diet and auto-
claved water supplied in bottles. Details of animal numbers used
for each experiment are included in the relevant figure legend,
and those were generally > 10 for tumour survival experiments
(both control and experimental groups) and > 3 for short-term
(up to 14 days) experiments. Mice were induced between 6 and
8 weeks of age and when weighing over 20 g. Genetic alleles
used throughout this study were as follows: vil-Cre-ERT2 (el
Marjou et al, 2004), Apcfl (Shibata et al, 1997), Huwe1fl (Zhao
et al, 2008), Mycfl (de Alboran et al, 2001), Ptenfl (Suzuki et al,
2001), Mcl1fl (Opferman et al, 2003), Lgr5-cre-ERT2 (Barker et al,
2007) and Ah-cre-ERT (Kemp et al, 2004). No randomisation was
used, and for scoring experiments, blinding of sample genotype to
the scorer was carried out. The experimental unit was designated
as single animals. Mice were housed (DETAILS). Recombination
in vil-Cre-ERT2 tumour models was induced using a single
intraperitoneal (IP) injection of 80 mg/kg tamoxifen. Recombina-
tion in vil-Cre-ERT2 short-term models (days 4 and 14) was
induced using a single IP injection of 80 mg/kg tamoxifen for two
consecutive days. Recombination in Lgr5-cre-ERT2 tumour models
was induced with a single IP injection of 120 mg/kg tamoxifen.
Recombination in Ah-cre-ERT tumour models was induced with a
single IP injection of 80 mg/kg tamoxifen and 80 mg/kg b-
naphthoflavone for four consecutive days. For cisplatin treatment,
tumour-bearing mice were injected with 7.5 mg/kg cisplatin IP
and sacrificed 6 h post-injection. For proliferation analysis, mice
were injected with 250 ll of BrdU (Amersham Biosciences) 2 h
before being sacrificed.
Immunohistochemistry
We used standard immunohistochemistry techniques during this
study. Details of primary antibodies and concentrations used can be
found in Appendix Supplementary Methods. We performed staining
on at least three mice of each genotype. Following blind scoring,
representative images were selected for each scoring.
Tissue sample scoring
Tissue samples were scored following various immunohistochemi-
cal staining. For normal tissue, the number of positive cells per
crypt or half-crypt was scored where appropriate. At least three
mice were used for each genotype. For tumour tissue, at least 20
images were captured at 40× magnification. The percentage of posi-
tive cells was scored for each image and the values averaged. At
least three mice were used for each genotype.
UbcH7 pulldown
In vitro binding assays were performed with the HUWE1-HECT
domain (amino acids 4,015–4,374 of human Huwe1) produced
as glutathione S-transferase (GST) fusion proteins. GST–HECT
fusion proteins were purified for wild-type Huwe1, the catalyti-
cally inactive Huwe1 mutant C4341A (C/A) and the two human
colorectal carcinoma-specific mutants (R4082H and K4204del).
The E2 subunit UbcH7 was produced as a His6 fusion protein
and eluted from Ni-NTA Agarose beads (Qiagen). The binding
reactions were performed as described (Zhao et al, 2008), and
the fraction of bound His-UbcH7 was measured by anti-histidine
Western blot.
Microarray analysis
One microgram of total intestinal RNA was reverse-transcribed to
cDNA and hybridised to Affymetrix Mouse Genome 430 2.0 microar-
rays. CEL files of six samples were normalised and analysed in
Partek Genomics Suite software. RMA normalisation and log2 trans-
formation of the data were followed by differential expression analy-
sis using ANOVA and post hoc linear contrasts between all pairs of
experimental conditions. Multiple test corrections were carried out
for P-values calculated. The fold change values for ranking genes of
interest were then considered (Appendix Table S1). Gene set enrich-
ment analysis was performed with chi-squared test with Yates’s
correction.
Mass spectrometry analysis
Tissue samples were lysed in 2% SDS by sonication. Lysates were
washed, reduced, alkylated, digested with trypsin and analysed on a
Q-Exactive mass spectrometer as previously reported (Farrell et al,
2014). Proteins were identified and quantified by label-free quan-
tification (LFQ) in the MaxQuant software suite (Cox et al, 2014) by
searching against the mouse Uniprot database, with carbamylation
of cysteines as a fixed modification and N-terminal acetylation and
methionine oxidation as variable modifications. The LFQ values
were transformed (log2) and grouped, 0 values imputed (normal
distribution shifted 2p) and statistically distinct protein groups iden-
tified (permutation-based FDR, 0.05) by using the Perseus software
suite (Tyanova et al, 2016).
HUWE1 expression analysis in human patients
We assembled an integrated database of colon cancer patient
samples measured by Affymetrix HGU133A, HGU133Aplus2 and
HGU133Av2 gene chips by employing the keywords “colon”,
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“cancer”, “GPL96”, “GPL571” and “GPL570” (respective platform
accession numbers for each above gene chip) in NCBI GEO (http://
www.ncbi.nlm.nih.gov/geo/). Only studies presenting raw data,
clinical data including survival length, and at least 30 patients were
included. Redundant samples (n = 777) were identified using the
ranked expression of all genes and removed from the final combined
database. The raw files were MAS5-normalised in the R environment
using the Affy Bioconductor library (http://www.bioconductor.org).
In the final analysis, samples with and without chemotherapy
(n = 244 and n = 318, respectively) were analysed separately.
Further experimental details are provided in Appendix Supple-
mentary Methods.
Expanded View for this article is available online.
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